Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin add-on to insulin in type 1 diabetes (phase 3)
2013-004674-97Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Dapagliflozin + insulin with Placebo + insulin (2 arms). Primary endpoint: Change in HbA1c from baseline at Week 24. Started Oct 2014; status: completed.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2013-004674-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004674-97.